Attovia Therapeutics, Inc. (NASDAQ:ATTO) Short Interest Up ∞ in August

Posted by Brenda Bartman on Aug 30th, 2026

Attovia Therapeutics, Inc. (NASDAQ:ATTO – Get Free Report) was the target of a large growth in short interest in the month of August. As of August 14th, there was short interest totaling 511,865 shares, a growth of ∞ from the July 30th total of 0 shares. Currently, 1.2% of the shares of the company are sold short. Based on an average daily volume of 732,925 shares, the days-to-cover ratio is currently 0.7 days.

Insiders Place Their Bets

In related news, major shareholder Life Sciences Xi L.P. Frazier acquired 588,235 shares of Attovia Therapeutics stock in a transaction that occurred on Thursday, August 6th. The stock was acquired at an average price of $17.00 per share, for a total transaction of $9,999,995.00. Following the transaction, the insider directly owned 6,154,213 shares of the company’s stock, valued at $104,621,621. This trade represents a 10.57% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Colin Walsh acquired 500,000 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were bought at an average price of $17.00 per share, with a total value of $8,500,000.00. Following the completion of the purchase, the director owned 3,020,632 shares in the company, valued at $51,350,744. The trade was a 19.84% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders have purchased 2,740,587 shares of company stock worth $47,269,979. 0.99% of the stock is currently owned by insiders.

Institutional Trading of Attovia Therapeutics

A hedge fund recently raised its position in Attovia Therapeutics stock. BlackRock Inc. increased its stake in Attovia Therapeutics, Inc. (NASDAQ:ATTO – Free Report) by 23.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 164,358 shares of the company’s stock after purchasing an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 at the end of the most recent quarter.

Attovia Therapeutics Stock Down 3.5%

ATTO stock opened at $20.70 on Friday. Attovia Therapeutics has a fifty-two week low of $16.15 and a fifty-two week high of $24.32.

About Attovia Therapeutics

(Get Free Report)

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.